U.S. Markets closed

It's Time to Face the Facts: Valeant Pharmaceuticals Is in Deep Trouble

newsfeedback@fool.com (Sean Williams)
It's Time to Face the Facts: Valeant Pharmaceuticals Is in Deep Trouble

Valeant's EBITDA-to-interest coverage ratio is getting exceptionally low.